Reference health
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
24/24 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
2 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 24 checked references that resolve
resolves10.1245/s10434-009-0809-6
Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
resolves10.1038/89901
Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
resolves10.1038/ncponc0736
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
resolves10.1038/nrc2545
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
resolves10.1016/j.ymthe.2006.05.008
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF
resolves10.1038/mt.2011.276
The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
resolves10.1038/mt.2011.39
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
resolves10.1172/JCI32727
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963
resolves10.1200/JCO.2009.24.3675
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
resolves10.1016/S1470-2045(08)70107-4
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
resolves10.1038/nature10358
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
resolves10.1038/mt.2008.143
The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma
resolves10.1200/JCO.2006.07.3049
Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria
resolves10.1016/S1470-2045(08)70285-7
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
resolves10.1158/1078-0432.CCR-10-1708
Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib
resolves10.1002/cncr.26255
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
resolves10.1128/JCM.42.2.601-609.2004
Smallpox and
<i>pan</i>
-Orthopox Virus Detection by Real-Time 3′-Minor Groove Binder TaqMan Assays on the Roche LightCycler and the Cepheid Smart Cycler Platforms
resolves10.2214/ajr.183.6.01831619
<b>CT Evaluation of the Response of Gastrointestinal Stromal Tumors After Imatinib Mesylate Treatment:</b> A Quantitative Analysis Correlated with FDG PET Findings
resolves10.1038/mt.2012.130
Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections
The 2 references without a DOI — listed, not checked
no DOI — not checkedHwang, T.H. et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol. Ther. 19, 1913–1922 (2011).
no DOI — not checkedWein, L.M., Wu, J.T. & Kirn, D.H. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res. 63, 1317–1324 (2003).
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1038/nm.3089"><img src="https://citestamp.com/citestamped/10.1038/nm.3089/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1038/nm.3089)